Complix NV

Technologiepark 94

9052 Zwijnaarde

BE

Complix NV

Foundation date

23/06/2008

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Complix is a biopharmaceutical company engaged in the discovery and development of Alphabodies™, a revolutionary class of biopharmaceuticals with exceptional properties. Alphabodies™ combine beneficial properties of small molecules with those of antibodies, and can address intracellular as well as extracellular disease targets that are undruggable by antibodies or small chemical drugs. Complix has developed a balanced pipeline of transformative protein therapeutics in oncology, autoimmunity/inflammation and viral diseases.

Upcoming events

Latest news

  • Bio Base Europe Pilot Plant successfully commissions a 75,000 L fermenter, demonstrating Vivici’s Vivitein™ BLG technology in industrial-scale precision fermentation

    9 hours ago

  • argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies

    1 day ago

  • ExeVir Announces Michael Garrett as New Chief Executive Officer

    Tuesday November 19th 2024